NVSEF NOVARTIS AG
- 100.620
- -1.380-1.35%
NOVARTIS AG News
Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
By Pierre Bertrand Novartis said the U.S. drug regulator decided to expedite the development of Scemblix, to treat adults newly diagnosed with leukemia. The Swiss pharmaceutical company said the U.S
Press Release: Sandoz Reports First Quarter 2024 Sales
Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE -- Strong first quarter performance, with net sales [1] of USD 2.5
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
Novartis to Buy Mariana Oncology for Up to $1.75 Bln in Boost to Radioligand Therapy Business
By Mauro Orru Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop cancer tr
CVS Stresses 'Margins Over Membership' to Offset Medicare Pressure
Press Release: MorphoSys AG Reports First Quarter 2024 Financial Results
MorphoSys AG Reports First Quarter 2024 Financial Results -- Entered into Business Combination Agreement to be acquired by Novartis for EUR 68.00 per share in cash, representing a total equity value
Analysts Have Conflicting Sentiments on These Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Siemens Healthineers AG (OtherSEMHF) and Novartis AG (Six Swiss: CH:NOVN)
Novartis Says New Malaria Drug Formulation Safe and Effective for Babies
Novartis AG (NVS) said Wednesday that data from a phase 2/3 study of a new formulation of Coartem to treat babies under 5 kilograms with malaria show that the new ratio and dose are safe and effective
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcidion Group Limited (ALC) and Novartis AG (Six Swiss: CH:NOVN)
Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy
By Adria Calatayud Novartis and Medicines for Malaria Venture said a new treatment for babies with malaria who weigh less than 5 kilograms showed positive efficacy and safety effects in a clinical st
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children
Novartis (NVS) said Tuesday it received approval from the US Food and Drug Administration for Lutathera as therapy for children with gastroenteropancreatic neuroendocrine tumors. The approval is based
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
By Dean Seal Novartis said federal regulators have approved its Lutathera therapy as a treatment for pediatric patients with certain gastroenteropancreatic neuroendocrine tumors. The Swiss pharmaceu
Earnings Call Summary | Novartis AG(NVS.US) Q1 2024 Earnings Conference
The following is a summary of the Novartis AG (NVS) Q1 2024 Earnings Call Transcript:Financial Performance:Novartis reported Q1 2024 sales were up 11% in constant currencies.Core operating income incr
Research Alert: CFRA Keeps Hold Opinion On Adss Of Novartis Ag
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $3 to $108,
Novartis Sees China and Biotech Acquisitions as Growth Drivers, CFO Says -- Market Talk
1257 GMT - Novartis eyes the expansion of its market presence in China and is on the look out to acquire further biotech companies, Chief Financial Officer Harry Kirsch says in a press call. The Swiss
Trending: Novartis Shares Climb on Guidance Lift
1240 GMT - Novartis is among the most mentioned companies across news items over the past 12 hours, according to Factiva data. The Swiss pharma giant's shares surged after it lifted its full-year guid
Novartis Guidance Lift Suggests Generics Effects to Ease -- Market Talk
1007 GMT - Novartis guidance lift reflects business growth and suggests a lower expected generics effects on sales this year, Stifel analyst Eric Le Berrigaud says. The Swiss pharma giant's sales and
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand
Novartis (NOVN.SW) on Tuesday raised its outlook for the full-year 2024 after reporting volume growth in first-quarter sales triggered by a strong demand for some of its blockbuster drugs. In 2024, th
Novartis Outlook Hike Looks Better Than Hoped -- Market Talk
0652 GMT - Novartis beat expectations for first-quarter sales and earnings and raised its 2024 outlook for both metrics by a wider margin than expected, which could trigger increases to consensus expe
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Outlook
Analysis
Price Target
No Data
